How ketogenic diets may starve cancer cells and boost treatment
Keto is being studied as a way to stress glucose-hungry tumors while supporting standard therapy. The idea is intriguing, but the evidence is still cancer-specific, experimental, and far from a cure.
Ketogenic diets have drawn cancer interest for a simple biological reason: they lower blood glucose and insulin, then shift the body toward using ketones for fuel. That switch may create metabolic stress for tumors that lean heavily on glucose, especially cells that struggle to adapt the way healthy tissue can. The appeal is not magic, it is mechanism, and that is exactly why the conversation keeps resurfacing around cancer care.
Why the Warburg effect matters
The basic logic goes back to Otto Warburg, who first described abnormal glucose metabolism in cancer cells in 1924. His observation later became known as the Warburg effect, the idea that many cancers take up glucose at unusually high rates and use it differently from normal cells. In keto circles, that detail matters because a diet that reduces circulating glucose seems, in theory, to squeeze a tumor’s preferred fuel supply.
That theory has been refined over time rather than abandoned. The ketogenic diet is often framed as a metabolic therapy, not a general wellness plan, because its target is cancer cell metabolism itself. A PubMed-indexed review also described keto as an adjuvant strategy, one meant to starve cancer cells and potentially make them more vulnerable to chemotherapy and radiotherapy.
From theory to treatment language
That distinction between mechanism and medicine is the whole story here. In a 2018 review in Nutrition, the ketogenic diet in cancer was described as a metabolic therapy aimed at targeting cancer cell metabolism rather than a standard dietary approach. That framing is important because it keeps keto in the lane of hypothesis-driven support, not standalone treatment.
The language used in later reviews is similarly careful. A 2021 PubMed-indexed review said the diet may be used as an adjuvant treatment to weaken cancer cells by limiting glucose availability. In practice, that means keto is being discussed as a possible partner to established cancer therapy, not a replacement for surgery, chemotherapy, radiotherapy, or immunotherapy.
What the reviews have actually looked at
The evidence base is broadening, but it is not settled. A systematic review and meta-analysis in Nutrients, published October 8, 2022, examined body composition and metabolic parameters in cancer patients on ketogenic diets. A 2024 systematic review and meta-analysis of randomized controlled trials looked at cancer-related variables as well, showing that the question has moved beyond one-off case reports and into more formal clinical assessment.
A 2025 review in Frontiers went a step further by saying ketogenic and fast-mimicking diets may have therapeutic effects in gastrointestinal cancers by reducing the availability of glucose to tumors. That is still a cautious statement, but it reflects where the field is heading: not broad claims about keto for every cancer, but more precise questions about which tumor types might be metabolically vulnerable.
A 2025 original research article in Frontiers in Nutrition also added to the discussion around dietary ketogenic metabolic therapy in cancer. The cumulative message from these papers is consistent: the idea has enough biologic logic to keep attracting serious study, but not enough proof to make broad treatment claims.
Where the strongest interest has gathered
Some cancers have attracted more attention than others because of how tightly they seem tied to glucose metabolism. Glioma is one of the clearest examples. A PubMed review focused on targeting the Warburg effect with ketogenic diets highlighted longstanding interest in brain tumors, especially malignant central nervous system tumors that are highly dependent on glucose.
That interest has reached formal trial registries. The U.S. National Cancer Institute lists DIET2TREAT, a study titled “A Ketogenic Diet in Combination with Standard-of-Care Therapy for the Treatment of Patients with Newly Diagnosed Glioblastoma.” Beyond glioblastoma, research has also tested ketogenic dietary intervention alongside immunotherapy in metastatic melanoma and metastatic kidney cancer. Those studies matter because they place keto inside real oncology protocols, where diet is being explored as an adjunct to drug-based treatment rather than a stand-alone intervention.
Why caution stays part of the picture
The scientific enthusiasm has never been matched by universal agreement. Cancer-center materials from Dartmouth Cancer Center and Memorial Sloan Kettering Cancer Center have both cautioned that evidence is still emerging and that patients should not treat keto as a proven cancer cure. That caution is not a shrug, it is a reminder that promising metabolic logic does not automatically translate into better survival, tumor control, or quality of life.
In 2022, the German Cancer Society’s Prevention and Integrative Oncology working group and the German Society for Nutritional Medicine issued a statement on ketogenic and low-carbohydrate diets in people with cancer. The statement underscored clinical interest while also emphasizing the need for careful guidance. That balance has become the defining posture around keto in oncology: watch closely, study carefully, and avoid overselling.
The complication that changed the tone
If keto sounds neatly anti-cancer, the newest preclinical work makes the picture messier. In August 2024, Columbia University Irving Medical Center reported a study linking keto diets to cancer metastasis. Then in September 2025, Cleveland Clinic researchers reported preclinical ovarian cancer findings connecting high-fat, low-carb diets to microbiome shifts and tumor-promoting activity. Those findings do not erase the older rationale, but they do sharpen the warning that metabolism cuts both ways.
That is why the field now reads like a live experiment in biology, not a settled diet prescription. Keto may stress some glucose-hungry tumors, may support standard therapy in select settings, and may make sense in carefully designed research protocols. It may also, depending on the cancer and the model, push biology in an unhelpful direction. The Warburg effect explains why the idea is so compelling, but the evidence still decides whether it becomes treatment.
Every story on Keto Diet Magazine is assembled by an automated editorial system that works from verified research, official records, and credible reporting, then clears automated accuracy and moderation checks before it goes live. The standards that system follows are set and overseen by the people who run the publication. Read our full editorial policy.
Did this article answer your question?
